Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2020 07:37 ET | Source: Zai Lab Limited

Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer

- The NORA study meets all primary and secondary endpoints - Largest randomized clinical trial (RCT) in ovarian cancer ever conducted in China - Individualized starting dose regimen shown to...
May 27, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Presentations at June Conferences

SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company...
May 18, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese...
May 13, 2020 09:39 ET | Source: Zai Lab Limited

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to...
May 06, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA

SHANGHAI, China, and SAN FRANCISCO, May 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for...
April 30, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference

SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today...
April 16, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces China’s NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment

SHANGHAI, China, and SAN FRANCISCO, April 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
April 08, 2020 06:00 ET | Source: Zai Lab Limited

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau Collaboration will also support enrollment of regional patients...
March 19, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates

-- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT SHANGHAI, China and SAN FRANCISCO, March 19, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based...
March 16, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA

SHANGHAI, China and SAN FRANCISCO, March 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...